Potassium Phosphate, Tribasic → Methyl 4'-(6-chloro-2-(((4aR,7R,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-5-yl)-[1,1'-biphenyl]-4-carboxylate

HRID 1050243Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1050243
Br[C:2]1[CH:7]=[CH:6][C:5]([C:8]2[N:13]=[C:12]3[N:14]=[C:15]([O:25][C@H:26]4[CH2:35][O:34][C@H:33]5[C@@H:28]([O:29][CH:30]([C:36]6[CH:41]=[CH:40][CH:39]=[CH:38][CH:37]=6)[O:31][CH2:32]5)[CH2:27]4)[N:16]([CH2:17][O:18][CH2:19][CH2:20][Si:21]([CH3:24])([CH3:23])[CH3:22])[C:11]3=[CH:10][C:9]=2[Cl:42])=[CH:4][CH:3]=1.C1(P(C2CCCCC2)C2C=CC=CC=2C2C(OC)=CC=CC=2OC)CCCCC1.CC1(C)C(C)(C)OB([C:80]2[CH:89]=[CH:88][C:83]([C:84]([O:86][CH3:87])=[O:85])=[CH:82][CH:81]=2)O1.P([O-])([O-])([O-])=O.[K+].[K+].[K+]>C([O-])(=O)C.[Pd+2].C([O-])(=O)C.O>[Cl:42][C:9]1[CH:10]=[C:11]2[N:16]([CH2:17][O:18][CH2:19][CH2:20][Si:21]([CH3:22])([CH3:23])[CH3:24])[C:15]([O:25][C@H:26]3[CH2:35][O:34][C@H:33]4[C@@H:28]([O:29][CH:30]([C:36]5[CH:41]=[CH:40][CH:39]=[CH:38][CH:37]=5)[O:31][CH2:32]4)[CH2:27]3)=[N:14][C:12]2=[N:13][C:8]=1[C:5]1[CH:6]=[CH:7][C:2]([C:80]2[CH:89]=[CH:88][C:83]([C:84]([O:86][CH3:87])=[O:85])=[CH:82][CH:81]=2)=[CH:3][CH:4]=1

Komponenten

7

Edukt 4

HCID 62657Potassium Phosphate, TribasicHCID 2773500Methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoateHCID 112698722-Dicyclohexylphosphino-2',6'-dimethoxybiphenylHCID 900448115-(4-bromophenyl)-6-chloro-2-(((4aR,7R,8aS)-2-phenylhexahydropyrano-[3,2-d][1,3]dioxin-7-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine

Produkt 1

HCID 131736056Methyl 4'-(6-chloro-2-(((4aR,7R,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridin-5-yl)-[1,1'-biphenyl]-4-carboxylate

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 167845palladium(II) acetateKatalysatorHCID 962WaterLösungsmittel

Reaktionsbedingungen

Temperatur
100 °C

Versuchsvorschrift

To a stirred solution of 5-(4-bromophenyl)-6-chloro-2-(((4aR,7R,8aS)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazo[4,5-b]pyridine (586 mg, 0.871 mmol), dicyclohexyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine (36 mg, 0.088 mmol), methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (297 mg, 1.132 mmol), and tribasic potassium phosphate (554 mg, 2.61 mmol) in tolune (2 mL) and water (0.1 mL) under nitrogen was added palladium acetate (10 mg, 0.045 mmol). The mixture was stirred at 100° C. for 16 hours, then allowed to cool to room temperature. The mixture was filtered, concentrated under reduced pressure, and chromatographed using a Biotage™ 50 g silica gel cartridge eluted with 0-30% EtOAc in 1:1 Hexane/DCM over 30 column volumes. The product fractions were concentrated under reduced pressure to provide the desired product as a foamy off-white solid. LC-MS: calculated for C39H42ClN3O7Si 727.25, observed m/e: 728.33 (M+H)+ (Rt 3.11/4 min).

Aufarbeitung

  1. temperatureto cool to room temperature
  2. filtrationThe mixture was filtered
  3. concentrationconcentrated under reduced pressure
  4. customchromatographed
  5. washeluted with 0-30% EtOAc in 1:1 Hexane/DCM over 30 column volumes
  6. concentrationThe product fractions were concentrated under reduced pressure

Quellen und Nachweise

ORD-Eintrag
ord-7658951755144f79a9aa0182d3a59d8d
Quelldatensatz
uspto-grants-2016_07
Patentnummer
US09382243B2

Notizen zur Reaktion

Wird geladen…